Disease relevance of Hepatic Veno-Occlusive Disease

• In contrast, pretransplantation TGF beta levels were significantly higher in patients in whom hepatic veno-occlusive disease or idiopathic interstitial pneumonitis developed than in the controls or the patients without these conditions [1].
• Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation [2].
• The dose-limiting toxicity of busulfan in BMT regimens is hepatic veno-occlusive disease (VOD), which occurs in approximately 20% to 40% of patients [3].
• A 2-yr-old child with idiopathic pulmonary hemosiderosis and autoimmune thrombocytopenia developed hepatic veno-occlusive disease after being treated with long-term, low-dose cyclophosphamide [4].
• In 111 of these patients who had haematological malignancy and who were prepared for transplant with cyclophosphamide 120 mg/kg and fractionated total body irradiation 12-14 Gy, the incidence of haemorrhagic cystitis and hepatic veno-occlusive disease was 13% and 3%, respectively [5].

High impact information on Hepatic Veno-Occlusive Disease

• Administration of matrix metalloproteinase inhibitors prevented the signs and histological changes associated with sinusoidal obstruction syndrome [6].
• Inhibition of matrix metalloproteinase-9 and matrix metalloproteinase-2 prevents the development of sinusoidal obstruction syndrome, establishing that matrix metalloproteinase inhibitors may be a therapeutically viable strategy for prevention [6].
• METHODS: In vitro and in vivo studies examined changes induced by monocrotaline, a pyrrolizidine alkaloid that induces sinusoidal obstruction syndrome in both humans and experimental animals [6].
• Hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine [7].
• Hepatic veno-occlusive disease caused by 6-thioguanine [8].

Chemical compound and disease context of Hepatic Veno-Occlusive Disease

• An infant with documented hepatic veno-occlusive disease due to ingestion of pyrrolizidine alkaloids is presented [9].
• Exposure to this metabolite was statistically significantly related to sinusoidal obstruction syndrome, bilirubin elevation, nonrelapse mortality, and survival, after adjusting for age and irradiation dose [10].
• Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat [11].
• Generally, the risk of hepatic veno-occlusive disease is increased with busulfan Css > 900 microg/L [12].
• Technetium-99m-sulfur colloid and pertechnetate blood pool scans in hepatic veno-occlusive disease: case report [13].

Anatomical context of Hepatic Veno-Occlusive Disease

• Hepatic veno-occlusive disease in pediatric stem cell recipients: successful treatment with continuous infusion of prostaglandin E1 and low-dose heparin [14].

Gene context of Hepatic Veno-Occlusive Disease

• In patients with hepatic veno-occlusive disease, the frequency of the PAI-1 4G allele is also increased (83.3% vs. 55.1%, NS) [15].
• In patients with hepatic veno-occlusive disease (VOD), another transplantation-related complication, the expression of IL-1 beta and TNF-alpha mRNA was increased but IL-6 mRNA expression showed little increase [16].
• Hepatic veno-occlusive disease in a patient with systemic lupus erythematosus [17].
• Diagnosis of hepatic veno-occlusive disease by plasminogen activator inhibitor-1 plasma antigen levels: a prospective analysis in 350 allogeneic hematopoietic stem cell recipients [18].
• CONCLUSIONS: Transfusion of platelet concentrates containing ABO-incompatible plasma increases the risk of hepatic veno-occlusive disease in young children treated with a busulfan-containing regimen [19].

Analytical, diagnostic and therapeutic context of Hepatic Veno-Occlusive Disease

• Favourable outcome of hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine, treated by portacaval shunt. Report of a case and review of the literature [20].
• Hepatic veno-occlusive disease (VOD) is a well-known complication of chemotherapy in Wilms tumor patients, particularly young children [21].

References